Scarica l'app Stockscreener
19.19
1.11%
0.21
Dopo l'orario di chiusura:
18.92
-0.27
-1.41%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MLTX Giù?
Forum
Previsione
Moonlake Immunotherapeutics Borsa (MLTX) Ultime notizie
[144] MoonLake Immunotherapeutics SEC Filing - Stock Titan
Why did MLTX stock rise after-hours today? - MSN
MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event - Stocktwits
MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data - Stocktwits
How Sonelokimab’s FDA Pre-BLA Milestone And EULAR Data At MoonLake Immunotherapeutics (MLTX) Has Changed Its Investment Story - simplywall.st
MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites - Stocktwits
MoonLake Immunotherapeutics (MLTX) Slides 1.7% as Biotech Sector Pressure Weighs, Support at $16.62 in FocusCommon Gap - newsline.com
InvestingPro Fair Value catches MoonLake before 63% biotech surge By Investing.com - Investing.com India
MoonLake (NASDAQ: MLTX) shareholders approve equity plan expansion and re-elect director - Stock Titan
MLTX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $45 - GuruFocus
Why Did MLTX Stock Rise After-Hours Today? - Stocktwits
Needham Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $30 - Moomoo
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Wedbush Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $34 - Moomoo
H.C. Wainwright reiterates Moonlake stock rating on axSpA data By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Moonlake stock rating on axSpA data - Investing.com
MLTX Q1 2026 Earnings: Pre-Revenue Biotech Misses EPS Estimates, Stock DeclinesLong-Term Guidance - newsline.com
MoonLake Immunotherapeutics (MLTX) Valuation After FDA Progress On Sonelokimab Draws Fresh Investor Attention - simplywall.st
Trading Systems Reacting to (MLTX) Volatility - Stock Traders Daily
MoonLake Immunotherapeutics CFO Trims His Stake. Should Investors Be Concerned? - AOL.com
MoonLake earnings in focus: BLA path for sonelokimab takes center stage - Investing.com
What Do MoonLake's Latest Week 40 HS Results Really Mean for Investors - Kavout
MoonLake Immunotherapeutics (MLTX) Price Target Raised to $45 At H.C. Wainwright on FDA Progress - Insider Monkey
MoonLake Secures Long-Term Manufacturing Capacity with Vetter Pharma - The Globe and Mail
MoonLake Immunotherapeutics Signs Manufacturing Agreement with Vetter Pharma – SEC 8-K Filing Details 8 - Minichart
MoonLake Immunotherapeutics enters supply and capacity agreements with Vetter - Investing.com UK
MoonLake Immunotherapeutics enters supply and capacity agreements with Vetter By Investing.com - Investing.com South Africa
MoonLake (NASDAQ: MLTX) secures Vetter supply and capacity agreements - Stock Titan
MoonLake Immunotherapeutics | 8-K: Current report - Moomoo
MLTX stock soars overnight after FDA backs skin drug filing — analyst sees over 300% upside on 'best-in-class' label - MSN
MLTX Stock Chart | MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ:MLTX) - ChartMill
HC Wainwright & Co. Maintains MoonLake Immunotherapeutics (MLTX) Buy Recommendation - MSN
How Moonlake Immunotherapeutics (MLTX) Affects Rotational Strategy Timing - Stock Traders Daily
MoonLake clears a key regulatory hurdle, and shares rocket - MSN
Should FDA Alignment on Sonelokimab’s HS Label Strategy Require Action From MoonLake Immunotherapeutics (MLTX) Investors? - simplywall.st
2.60%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):